Chemotherapy Response in Ovarian Cancer Patients
Author Information
Author(s): G. Blackledge, F. Lawton, C. Redman, K. Kelly
Primary Institution: University of Birmingham, UK
Hypothesis
Factors other than drug efficacy affect patient response in phase II chemotherapy studies for ovarian cancer.
Conclusion
The interval from previous treatment to entry into a phase II study and FIGO stage are significant predictors of response to chemotherapy in ovarian cancer.
Supporting Evidence
- Patients who progressed on treatment within 3-6 months had a response rate of less than 10%.
- Discriminant analysis predicted 89% of non-responders and 75% of responders correctly.
- An interval of greater than 21 months between treatments was associated with a high response rate.
Takeaway
Doctors found that how long it's been since a patient last had treatment and how advanced their cancer is can help predict if they'll respond to new chemotherapy.
Methodology
Retrospective analysis of five phase II chemotherapy trials with univariate and multivariate analyses to identify predictive factors.
Potential Biases
Potential bias in patient selection and response assessment.
Limitations
The study is small and needs replication.
Participant Demographics
Patients with biopsy-proven epithelial ovarian carcinoma who had received at least first-line treatment.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website